C-T581Cyclone Therapeutics
Trappsol Cyclo, rare neurological disorders
clearingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-T581
C-T581C-T581Trappsol Cyclo, rare neurological disorders
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Approximately 90 patients, aged 50 to 80 years, with a diagnosis of early Alzheimer's disease will take part in this research study. This study will be conducted in the US. There will be 3 treatment groups: 2 Active doses and 1 group will receive placebo completely by chance. Patients, caregiver, Sponsor, nor study staff will know which treatment is assigned. There are 3 periods in this study: Screening to confirm suitability, Treatment to receive study medication, and Follow-up to check overall health post-participation
A prospective, randomized, double-blind, placebo controlled, multi-center therapeutic study for patients age 3 and older with confirmed diagnosis of Niemann Pick disease type C1 (NPC1). The objective of this study is to evaluate the safety, tolerability and efficacy of 2000 mg/kg dose of Trappsol Cyclo (hydroxypropyl betacyclodextrin) administered intravenously compared to standard of care. An open-label sub-study in countries following European Medicines Agency (EMA) guidance will enroll asymptomatic or symptomatic patients from infancy up to age 3 to evaluate safety in that population.
The purpose of this study is to provide continued access to treatment for NPC-1 after participation and completion of the Phase I trial CTD-TCNPC-101, when administered at doses of 1500 mg/kg and 2500 mg/kg by slow IV infusion over a period of 8 to 9 hours every two weeks.
This research study is being conducted to find out whether Trappsol® Cyclo™, an experimental treatment for people with Niemann Pick disease Type C (NPC-1) is safe at 2 different dose levels and what effects it has on people who have this condition. NPC-1 is caused by a defect in the protein which is important for the transport of fatty substances like cholesterol out of cells. Without this protein, fats build up in the cells ultimately leading to organ damage. The way in which this experimental treatment works is not fully understood but laboratory experiments have shown that it can potentially remove cholesterol build up from the cells in people who have NPC-1. Approximately 12 patients will be asked to take part in this research study for up to 20 weeks (w) in total (including screening. treatment and follow-up). Recruitment is expected to take 6- 9 months.Patients who take part will receive treatment by an intravenous infusion every two weeks. The study will look at what the body does to the drug as well as what the drug does to the body by taking and examining blood and urine samples. A sample(s) of cerebrospinal fluid (CSF) will be taken by lumbar puncture during the first treatment dose and may be collected during subsequent doses. Liver and skin biopsy specimens will be taken to assess filipin staining. Cholesterol metabolism will be investigated in liver samples and splenic and hepatic elasticity will be assessed by ultrasound. Patients will also have their hearing tested, be asked questions by their doctor as well completing questionnaires to help assess any changes in their condition during treatment.This study is being sponsored and funded by CTD holdings Inc. It is planned to be run in the USA,.
This research study is being conducted to find out whether Trappsol® Cyclo™, an experimental treatment for people with Niemann-Pick disease Type C1 (NPC-1) is safe at 3 different dose levels and what effects it has on people who have this condition. NPC-1 is caused by a defect in a protein which is important for the transport of fatty substances like cholesterol out of cells. Without this protein, fats build up in the cells ultimately leading to organ damage. The way in which this experimental treatment works is not fully understood but laboratory experiments have shown that it can potentially remove cholesterol build up from the cells in people who have NPC-1. Approximately 12 patients will be asked to take part in this research study for up to 56 weeks in total. recruitment is expected to take 9 months.Patients who take part will receive treatment by an intravenous infusion every two weeks. The study will look at what the body does to the drug as well as what the drug does to the body by taking and examining blood and urine samples. Samples of Cerebrospinal fluid (CSF) are also taken by lumbar puncture during and following the first treatment dose. Patients will also have their hearing tested, be asked questions by their doctor as well completing questionnaires to help assess any changes in their condition during treatment. Optional assessments patients can choose to take part in include liver biopsies, additional lumbar punctures for CSF.examinations to see if the drug is affecting these. This study is being sponsored and funded by CTD holdings INC. It is planned to be run in the UK, Italy, and Sweden.
Rafael Holdings and Cyclo Therapeutics announce merger Products Data Feature Plans Request Demo Sign Up for Free Rafael Holdings and Cyclo Therapeutics announce merger 30 August 2024 Rafael Holdings has entered into a definitive merger agreement with Cyclo Therapeutics to accelerate the development of Trappsol Cyclo , a treatment for Niemann-Pick disease type C1 . As part of the merger, Rafael will issue shares of its Class B common stock to Cyclo’s shareholders, valuing Cyclo at $0.95 per share. The valuation of Rafael will be based on its cash value, marketable securities, and certain other
Cyclo Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results - cyclotherapeutics Purpose Overview Team Leadership Team Patients and Families Our Commitment Patient Resources Community Stories Ongoing Clinical Trials TransportNPC: Phase 3 Study in Niemann-Pick Disease Type C Expanded Access Program Science Trappsol ® Cyclo™ Scientific Publications Pipeline Pipeline Niemann-Pick Disease Type C News/Events News Email Alerts Contact Select Page News Email Alerts News Cyclo Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results May 15, … of directors and welcomed strategic investor Rafael Holdings in two successful fund raises completed following the end of the quarter. Our commitment to the NPC community remains steadfast and strong; we are here with you,” commented N. Scott Fine, CEO of Cyclo Therapeutics. Recent Highlights TransportNPC™ pivotal study on track to be 50% enrolled by the end of May 2023; Company on track to complete enrollment by year end; Completed financings with gross proceeds
Scientific Publications - cyclotherapeutics Purpose Overview Team Leadership Team Patients and Families Our Commitment Patient Resources Community Stories Ongoing Clinical Trials TransportNPC: Phase 3 Study in Niemann-Pick Disease Type C Expanded Access Program Science Trappsol ® Cyclo™ Scientific Publications Pipeline Pipeline Niemann-Pick Disease Type C News/Events News Email Alerts Contact Select Page Trappsol ® Cyclo™ Scientific Publications Scientific Publications 2025 Trappsol ® Cyclo™ (HPβCD) for the Long-Term Treatment of Niemann-Pick Type C: Efficacy and Safety Data from 4 Clinical St
Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL) - The Globe and Mail Home Canada Business Investing Life Opinion World Politics Personal Finance Culture Sports More More Latest in More Real Estate Drive Watchlist For You Events Find clarity in the chaos. Subscribe now and save 70% Subscribe Digital access Digital + home delivery TSX 0.37 % S&P 500 -0.05 % DOW -0.09 % NASDAQ -0.24 % Oil -3.74 % Dollar 0.05 % Gold 1.2 % tsx movers: CNQ-T -0.3 % BB-T + 10.33 % SU-T -0.87 % TRP-T -0.77 % This section co … -based therapeutics company. The Company's primary focus has been to invest in, fund, and develop novel cancer therapies. We seek to expand our portfolio through strategic opportunistic investments and or acquisitions within and outside the pharmaceutical and biotech sectors. About Cyclo Therapeutics Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living … nstitute Contact us Address and Phone Number Standards Editors Staff SecureDrop Submit an article Reader services Account Settings Customer Support Subscriptions Member Benefits Privacy Settings About us Company information Work at The Globe Accessibility Editorial Code of Conduct Sustainability Licensing & Permissions Election Advertising Registry Modern Slavery Report AI Guidelines Subscribe Digital + Home Delivery Digital Access Globe2Go The New York Times Globe Email … nstitute Contact us Address and Phone Number Standards Editors Staff SecureDrop Submit an article Reader services Account Settings Customer Support Subscriptions Member Benefits Privacy Settings About us Company information Work at The Globe Accessibility Editorial Code of Conduct Sustainability Licensing & Permissions Election Advertising Registry Modern Slavery Report AI Guidelines Jump to footer navigation © Copyright 2026 The Globe and Mail Inc. All rights reserved. 3
Science - cyclotherapeutics Purpose Overview Team Leadership Team Patients and Families Our Commitment Patient Resources Community Stories Ongoing Clinical Trials TransportNPC: Phase 3 Study in Niemann-Pick Disease Type C Expanded Access Program Science Trappsol ® Cyclo™ Scientific Publications Pipeline Pipeline Niemann-Pick Disease Type C News/Events News Email Alerts Contact Select Page Science Cyclo Therapeutics, LLC, A Rafael Company © 2026 Privacy Policy Disclaimer Press Releases Cyclo Chemicals Contact Follow Follow Follow We use cookies on our website to give you the most relevant exper
Cyclo Therapeutics Appoints Lise Lund Kjems, MD, PhD as Chief Medical Officer - cyclotherapeutics Purpose Overview Team Leadership Team Patients and Families Our Commitment Patient Resources Community Stories Ongoing Clinical Trials TransportNPC: Phase 3 Study in Niemann-Pick Disease Type C Expanded Access Program Science Trappsol ® Cyclo™ Scientific Publications Pipeline Pipeline Niemann-Pick Disease Type C News/Events News Email Alerts Contact Select Page News Email Alerts News Cyclo Therapeutics Appoints Lise Lund Kjems, MD, PhD as Chief Medical Officer Sep 27, 2021 – Dr. Kjems is a l … y of Copenhagen, Denmark. Additionally, she completed her postdoctoral research fellowship at the University Department of Medicine, Edinburgh Scotland and Université Catholique de Louvain. Dr. Cox added, “Dr. Kjems is a strong addition to the Cyclo Therapeutics team. With my transition to the SAB, I am pleased to continue working alongside Dr. Kjems and the incredible team at Cyclo Therapeutics with the united vision to provide patients and families with life-changing
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Cyclo Therapeutics Provides Clinical Program Update and Highlights Recent Achievements - cyclotherapeutics Purpose Overview Team Leadership Team Patients and Families Our Commitment Patient Resources Community Stories Ongoing Clinical Trials TransportNPC: Phase 3 Study in Niemann-Pick Disease Type C Expanded Access Program Science Trappsol ® Cyclo™ Scientific Publications Pipeline Pipeline Niemann-Pick Disease Type C News/Events News Email Alerts Contact Select Page News Email Alerts News Cyclo Therapeutics Provides Clinical Program Update and Highlights Recent Achievements Jan 11, 2023 Contin
Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement Overview Who We Are Team Community Involvement Careers Profile Services What We Do Mergers & Acquisitions Capital Raising Fairness & Solvency Advisory Services Valuations Restructurings Industries Transactions Our Deals Transactions Case Studies Knowledge Our Insights Florida Sponsor Reports Aviation Deal Reports Tech Deal Reports Whitepapers Resources News Our News In the News Announcements Media Room Contact Get in Touch Disclosures and Privacy Policy Contact Overview Team Industries Community Involveme … rtible notes through closing. Following the closing, Rafael Holdings intends to fund the TransportNPC™ clinical trial to its 48-week interim analysis. The boards of directors of Rafael Holdings and Cyclo Therapeutics have approved this transaction and expect it to close in late 2024, pending approval of the companies’ shareholders, the effectiveness of a registration statement to register the shares of Class B common stock of Rafael Holdings to be issued in the transaction an
Clinical Trial Manager - cyclotherapeutics Purpose Overview Team Leadership Team Patients and Families Our Commitment Patient Resources Community Stories Ongoing Clinical Trials TransportNPC: Phase 3 Study in Niemann-Pick Disease Type C Expanded Access Program Science Trappsol ® Cyclo™ Scientific Publications Pipeline Pipeline Niemann-Pick Disease Type C News/Events News Email Alerts Contact Select Page Leadership Team Clinical Trial Manager Full Job Description, Full Time Remote As an employee of Cyclo Therapeutics, Inc., you will actively contribute to our ongoing Phase 3 Pivotal trial and b … specific variable or performance-based bonus and or other compensation elements Apply Here Our Pipeline Our Science Sign up for Alerts Trappsol ® Cyclo™ is not currently approved for any indication. Third-party websites are provided for convenience only. Cyclo Therapeutics, LLC does not approve of, or endorse any of the content. Cyclo Therapeutics, LLC does not maintain, control or monitor the content of third-party websites in any way. Cyclo Therapeutics, LLC, A Rafael Compa
Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement - cyclotherapeutics Purpose Overview Team Leadership Team Patients and Families Our Commitment Patient Resources Community Stories Ongoing Clinical Trials TransportNPC: Phase 3 Study in Niemann-Pick Disease Type C Expanded Access Program Science Trappsol ® Cyclo™ Scientific Publications Pipeline Pipeline Niemann-Pick Disease Type C News/Events News Email Alerts Contact Select Page News Email Alerts News Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merg … closing combined Company will have approximately $13.7 million cash on hand to fund operations into 2H 2024 Upcoming milestones include completion of enrollment in pivotal Phase 3 clinical trial in NPC1, reporting top line data and preparation for NDA submission GAINESVILLE, Fla. & SOUTH SAN FRANCISCO, Calif. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company focused on d
EX-99.1 8 ex_717503.htm EXHIBIT 99.1 ex_717503.htm Exhibit 99.1 Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement Cyclo Therapeutics ’ TransportNPC ™ Phase 3 clinical trial for Trappsol ® Cyclo ™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 NEWARK, NJ and GAINESVILLE, FL – August 22, 2024 (GLOBE NEWSWIRE) - Rafael Holdings, Inc. (NYSE: RFL), and Cyclo Therapeutics, Inc. ( … rtible notes through closing. Following the closing, Rafael Holdings intends to fund the TransportNPC™ clinical trial to its 48-week interim analysis. The boards of directors of Rafael Holdings and Cyclo Therapeutics have approved this transaction and expect it to close in late 2024, pending approval of the companies’ shareholders, the effectiveness of a registration statement to register the shares of Class B common stock of Rafael Holdings to be issued in the tr
Financial Information - cyclotherapeutics Purpose Overview Team Leadership Team Patients and Families Our Commitment Patient Resources Community Stories Ongoing Clinical Trials TransportNPC: Phase 3 Study in Niemann-Pick Disease Type C Expanded Access Program Science Trappsol ® Cyclo™ Scientific Publications Pipeline Pipeline Niemann-Pick Disease Type C News/Events News Email Alerts Contact Select Page News Email Alerts Financial Information Our Pipeline Our Science Sign up for Alerts Trappsol ® Cyclo™ is not currently approved for any indication. Third-party websites are provided for convenie
Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL) - cyclotherapeutics Purpose Overview Team Leadership Team Patients and Families Our Commitment Patient Resources Community Stories Ongoing Clinical Trials TransportNPC: Phase 3 Study in Niemann-Pick Disease Type C Expanded Access Program Science Trappsol ® Cyclo™ Scientific Publications Pipeline Pipeline Niemann-Pick Disease Type C News/Events News Email Alerts Contact Select Page News Email Alerts News Cyclo Therapeutics Announces Closing of Strategic Inv … therapeutics company. The Company’s primary focus has been to invest in, fund, and develop novel cancer therapies. We seek to expand our portfolio through strategic opportunistic investments and or acquisitions within and outside the pharmaceutical and biotech sectors. About Cyclo Therapeutics Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living
MIT License Agreement for Alzheimer's Treatment | Cyclo Therapeutics, A Rafael Company posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join … laboration with Merakris Therapeutics and received the Best Laboratory Research Award at SAWC last month. Download the poster for full results on cfAF distribution, LC-MS/MS detection, and wound closure outcomes: https://bit.ly/4233Ei5 7 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in 2,718 followers View Profile Connect More from this author Our Key Takeaways from the NPUK Annual Family Conference & Workshop Cyclo Therapeutics, A Rafael Comp
Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc. - cyclotherapeutics Purpose Overview Team Leadership Team Patients and Families Our Commitment Patient Resources Community Stories Ongoing Clinical Trials TransportNPC: Phase 3 Study in Niemann-Pick Disease Type C Expanded Access Program Science Trappsol ® Cyclo™ Scientific Publications Pipeline Pipeline Niemann-Pick Disease Type C News/Events News Email Alerts Contact Select Page News Email Alerts News Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, In … based therapeutics company. Rafael’s primary focus has been to invest in, fund, and develop novel cancer therapies. Rafael seeks to expand our portfolio through strategic opportunistic investments and or acquisitions within and outside the pharmaceutical and biotech sectors. About Cyclo Therapeutics Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families l
Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private Placement - cyclotherapeutics Purpose Overview Team Leadership Team Patients and Families Our Commitment Patient Resources Community Stories Ongoing Clinical Trials TransportNPC: Phase 3 Study in Niemann-Pick Disease Type C Expanded Access Program Science Trappsol ® Cyclo™ Scientific Publications Pipeline Pipeline Niemann-Pick Disease Type C News/Events News Email Alerts Contact Select Page News Email Alerts News Cyclo Therapeutics Announces E … therapeutics company. The Company’s primary focus has been to invest in, fund, and develop novel cancer therapies. We seek to expand our portfolio through strategic opportunistic investments and or acquisitions within and outside the pharmaceutical and biotech sectors. About Cyclo Therapeutics Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life- changing medicines through science and innovation for patients and families livin
Contact - cyclotherapeutics Purpose Overview Team Leadership Team Patients and Families Our Commitment Patient Resources Community Stories Ongoing Clinical Trials TransportNPC: Phase 3 Study in Niemann-Pick Disease Type C Expanded Access Program Science Trappsol ® Cyclo™ Scientific Publications Pipeline Pipeline Niemann-Pick Disease Type C News/Events News Email Alerts Contact Select Page Contact Us Cyclo Therapeutics, LLC, A Rafael Company Mailing/Ordering Address: P.O. Box 1180 Alachua, FL 32616-1180 Physical Address: 6714 NW 16th Street, Suite B Gainesville, FL 32653 Email : info@cyclothera
The successful merger with Rafael Holdings marks a new chapter as we focus on the future, with the vision of developing life-changing medicines through science. This is just the beginning of our journey to make a meaningful difference. Follow us—NYSE: RFL #CYTH #RFL #NPC1 | Cyclo Therapeutics, Inc.
Pipeline - cyclotherapeutics Purpose Overview Team Leadership Team Patients and Families Our Commitment Patient Resources Community Stories Ongoing Clinical Trials TransportNPC: Phase 3 Study in Niemann-Pick Disease Type C Expanded Access Program Science Trappsol ® Cyclo™ Scientific Publications Pipeline Pipeline Niemann-Pick Disease Type C News/Events News Email Alerts Contact Select Page Pipeline Niemann-Pick Disease Type C Pipeline Leveraging Scientific Innovation to Advance Our Pipeline Ongoing Collaboration with University of the Witwatersrand, Johannesburg to Advance Trappsol® Cyclo™ Pla
Rafael Holdings Completes Merger with Cyclo Therapeutics --> Accessibility: Skip TopNav Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 March 26, 2025 06:50 ET | Source: Rafael Holdings, Inc. Rafael Holdings, Inc. NEWARK, N.J. and GAINESVILLE, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Rafae … calendar 2026 The company has had a pre-NDA meeting with the FDA and expects to submit an NDA in second half of calendar 2026 The... Read More
EX-99.1 4 ex_572019.htm EXHIBIT 99.1 ex_572019.htm Exhibit 99.1 Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement Combined company will operate as Cyclo Therapeutics with primary focus on advancing Trappsol ® Cyclo ™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) At closing combined Company will have approximately $13.7 million cash on hand to fund operations into 2H 2024 Upcoming milestones include completion of enrollment in pivotal Phase 3 clinical trial in NPC1, reporting top
Press Releases Archives - cyclotherapeutics Purpose Overview Team Leadership Team Patients and Families Our Commitment Patient Resources Community Stories Ongoing Clinical Trials TransportNPC: Phase 3 Study in Niemann-Pick Disease Type C Expanded Access Program Science Trappsol ® Cyclo™ Scientific Publications Pipeline Pipeline Niemann-Pick Disease Type C News/Events News Email Alerts Contact Select Page Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years Old by mpzzqmvj | Sep 16, 202
Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals - cyclotherapeutics Purpose Overview Team Leadership Team Patients and Families Our Commitment Patient Resources Community Stories Ongoing Clinical Trials TransportNPC: Phase 3 Study in Niemann-Pick Disease Type C Expanded Access Program Science Trappsol ® Cyclo™ Scientific Publications Pipeline Pipeline Niemann-Pick Disease Type C News/Events News Email Alerts Contact Select Page News Email Alerts News Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals Mar 26, 2025 Cy
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Log On Home Join Sign in --> Sign in Home Search Filings Search Exhibits Search & Alert Archived Filings Queued Filings Insider Research EDGAR Company More ... Sign in Sign in Sign in name Password Next time automatically sign me in Sign in I need help with my password Click here to join Copyright © 2024 www.secdatabase.com. All Rights Reserved. EDGAR® and SEC® are trademarks of the U.S. Securities and Exchange Commission. SECDatabase's products and services are not affiliated with or approved by the U.S. Securities and Exchange Commission. Contact Us |
Cyclo Therapeutics, Inc. - AnnualReports.com Menu BROWSE BY Exchanges Industry Other Filters BROWSE BY Exchanges Industry Other Filters 0 Cyclo Therapeutics, Inc. Ticker CYTH Exchange NASDAQ More Industry Drug Manufacturers - Other More Sector Healthcare More 1-10 Employees Based in Gainesville, Florida Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with disease. The Company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is
EX-99.1 2 ea026090801ex99-1_rafael.htm INVESTOR PRESENTATION 附件99.1 納斯達克：RFL 2025年10月 | 投資者演示 前瞻性聲明 本演示文稿中的某些信息涉及未來事件或未來的業務和財務表現。此類聲明構成了1995年《私人證券訴訟改革法案》所定義的前瞻性信息。這些聲明僅爲預測，實際事件或結果可能由於各種原因而與討論的內容有所不同，其中包括在Rafael Holdings, Inc.的公開文件和其他出版物中描述的風險。前瞻性聲明可以通過諸如「預期」、「預計」、「計劃」、「打算」、「相信」、「估計」、「目標」等詞彙以及其他類似的表達方式識別，這些詞彙表明趨勢和未來事件。本演示文稿中使用的市場數據和某些其他統計信息基於獨立行業出版物、政府出版物、市場研究公司報告或其他獨立來源。部分數據也基於公司的善意估計。此外，本演示文稿包括對科學活動及其成果的總結，這些內容經過濃縮以便於讀者獲得一般性的理解。關於Rafael Holdings, Inc.及其子公司的信息僅供信息參考之用，並不構成在任何州出售或徵求購買任何證券的要約。可能導致公司結果與前瞻性聲明中所表達的結果產生重大差異的因素包括但不限於：公司需要額外資本；公司依賴其Trappsol® Cyclo產品，該產品可能永遠不會獲得監管批准；公司在獲得監管批准後能否將其擬議的藥品
Cyclo Therapeutics | Grafa Skip to main content Hub News Signals Assets Assets Market Economy Country Learn Channel Company Livestream Grafa TV Quote Forex Quote Settings Home company cyclo therapeutics Cyclo Therapeutics — Company Overview, News & Financial Data Cyclo Therapeutics develops therapies for rare diseases, focusing on Niemann-Pick Disease and innovative drug delivery solutions. Cyclo Therapeutics About Cyclo Therapeutics Cyclo Therapeutics (NASDAQ:CYTH) is a biotechnology company focused on the development of innovative therapies for diseases with a critical need for treatment
ctdh20220301_8k.htm false 0000922247 0000922247 2022-02-28 2022-02-28 0000922247 ctdh:CommonStockCustomMember 2022-02-28 2022-02-28 0000922247 ctdh:WarrantsToPurchaseCommonStockCustomMember 2022-02-28 2022-02-28 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported)           February 28, 2022   CYCLO THERAPEUTICS, INC. (Exact name of registrant as specified in char … entage of the Company’s outstanding shares of common stock on the date of grant, in each case, as set forth below:   Officer   Initial Option Grant     Annual Option Grant   N. Scott Fine     74,907       0.89 % Michael Lisjak     31,141       0.37 % Joshua Fine     31,141       0.37 % Jeffrey Tate     31,141       0.37 %     ● In
Cyclo Therapeutics Achieves Last Patient Last Visit in Phase 3 TransportNPC Trial | Josh Fine posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to jo … k UK (NPUK) AbbyStrong Fights NPC Australian NPC Disease Foundation Inc Firefly Fund NiemannPick India Ara Parseghian Medical Research Fund Cyclo Therapeutics, A Rafael Company 2,718 followers 2w Edited We have announced the completion of last patient last visit for Cyclo’s pivotal phase 3 TransportNPC™ study evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C. https://lnkd.in/eMtWbwiQ News - cyclotherapeutics https://cyclotherapeutics.com 41 2 Commen
Cyclo Therapeutics Announces Closing of Underwriters' Option to Purchase Additional Shares of Common Stock in Connection with its Underwritten Public Offering - cyclotherapeutics Purpose Overview Team Leadership Team Patients and Families Our Commitment Patient Resources Community Stories Ongoing Clinical Trials TransportNPC: Phase 3 Study in Niemann-Pick Disease Type C Expanded Access Program Science Trappsol ® Cyclo™ Scientific Publications Pipeline Pipeline Niemann-Pick Disease Type C News/Events News Email Alerts Contact Select Page News Email Alerts News Cyclo Therapeutics Announces
Cyclo Therapeutics Commences Commercial-Scale Manufacturing for Trappsol® Cyclo™ - cyclotherapeutics Purpose Overview Team Leadership Team Patients and Families Our Commitment Patient Resources Community Stories Ongoing Clinical Trials TransportNPC: Phase 3 Study in Niemann-Pick Disease Type C Expanded Access Program Science Trappsol ® Cyclo™ Scientific Publications Pipeline Pipeline Niemann-Pick Disease Type C News/Events News Email Alerts Contact Select Page News Email Alerts News Cyclo Therapeutics Commences Commercial-Scale Manufacturing for Trappsol® Cyclo™ Jul 27, 2 … ceived positive feedback supporting the Company’s development strategy to submit an Initial New Drug (IND) application for a Phase 2 study of intravenous Trappsol ® Cyclo™ in the treatment of early Alzheimer’s disease. The Company is on track to file its IND for a Phase 2 study of Alzheimer’s disease in the second half of 2021. About Cyclo Therapeutics Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-
Jeffrey L. Tate - Director, COO & CQO at Cyclo Therapeutics | The Org Platform Enrich Pricing Log in Sign up Cyclo Therapeutics Jeffrey L. Tate Unverified Jeffrey L. Tate Director, COO & CQO Contact Dr. Tate is a seasoned executive with more than 30 years of experience in the biotechnology, pharmaceutical and nutritional supplements industries including: branded generic drugs, intellectual property strategy, product development, and cGMP manufacturing. He is intimately familiar with food and drug marketing approval procedures, documentation and strategy in U.S. and foreign markets, e
Board of Directors - cyclotherapeutics Purpose Overview Team Leadership Team Patients and Families Our Commitment Patient Resources Community Stories Ongoing Clinical Trials TransportNPC: Phase 3 Study in Niemann-Pick Disease Type C Expanded Access Program Science Trappsol ® Cyclo™ Scientific Publications Pipeline Pipeline Niemann-Pick Disease Type C News/Events News Email Alerts Contact Select Page Leadership Team Board of Directors Markus W. Sieger Chairman of the Board Mr. Sieger is the President and CEO of Polpharma Group, a large regional pharmaceutical company, focused on Poland, Russia … serves as a Management Advisor to ValueAct Capital, a San Francisco-based hedge fund. Mr. Shanahan joined our Board of Directors in June 2016. Mr. Shanahan received his BA from Dartmouth College and attended the University of California, International Christian University in Tokyo, and the University of the Philippines. Randall M. Toig, M.D. Director Dr. Randall M Toig, M.D. is an associate professor at Northwestern University, Northwestern Memorial Hospital. He is also a wel … from the University of Maryland School of Medicine and completed a postdoctoral fellowship in Neurology at the Albert Einstein College of Medicine. She is author on over 40 scientific publications in peer reviewed journals. She is a member of the Scientific Advisory Board of NeuroCuresNY, Inc., Board of Directors of Burke Neurological Institute, and an Advisor to the Westchester County Biosciences Task Force. Shawn Cross Director Shawn Cross has been a director of the Company
Rafael Holdings, Inc. - Executive Bio, Top Executies, and Transitions - Equilar ExecAtlas Request a Demo Engage Executives. Unlock Deals. ExecAtlas delivers real-time insight into who-knows-who, paving the way for warm introductions that create opportunities. Search for an Executive Trusted by Industry Leaders Trusted by Industry Leaders Featured Organization RFL - Rafael Holdings, Inc. www.rafaelholdings.com Company Details Description Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and
Directors News | Investors CONTACT US Rafael Holdings Navigation Cyclo Therapeutics Leadership Board of Directors Executive Management Leadership Board of Directors Executive Management Investors Investors Directors Board of Directors Howard S. Jonas Inside Director Chairman of the Board and Chief Executive Officer Howard S. Jonas has served as Chairman of the Board of Directors of the Company since August 17, 2017 and as Executive Chairman since June 13, 2022. He has served as Chief Executive Officer since July 2025 and previously served in that capacity from March 8, 2018 through … pmental Therapeutics program at CUIMC. Dr. Stein completed an Internal Medicine Residency at Montefiore Medical Center from 1998 to 2001 and an Hematology/Oncology Fellowship at Mount Sinai Medical Center from 2001 to 2004. From 2004 until 2018 Dr. Stein worked as a medical oncologist at the Cancer Institute of New Jersey, Rutgers University. Dr. Stein has extensive experience leading early-stage clinical trials with novel therapeutics and has worked with multiple small to mi … f Physicians and Surgeons in 1981. Dr. Weiss also did a Post-Graduate Fellowship at Columbia University Institute of Cancer Research from 1976-1977. Susan Y. Bernstein Inside Director Susan Y. Bernstein has served as a director since January, 2024. Since 2018, Ms. Bernstein has served as Co-Owner/Director of Sales and Marketing for the Best Western PLUS Morristown Inn which is the #1 hotel in Morristown on TripAdvisor. From November 2013 through September 2017, Ms.
After ten years as CEO of Cyclo Therapeutics, we share this video with deep gratitude for Scott’s decade of leadership and service to the NPC community and the many families he has supported along the way. Scott’s dedication has always been rooted in love. His late wife, Cathy, was the inspiration behind his unwavering commitment. Her kindness, strength, and deep sense of purpose shaped a mission that has touched and uplifted so many families, and her legacy continues to live on through this community. We wish Scott the very best in his next chapter at Rafael and thank him for the lasting impa
2026 CORE Symposium Solutions Planning Enrollment Forecaster Activation Staff Training Document Exchange Enrollment Clinical Trial Websites Recruitment Technology Recruitment Technology Engagement Site Engagement Patient Engagement Analytics Platforms and Complance Insights About CONTACT US Solutions Planning Enrollment Forecaster Activation Staff Training Document Exchange Enrollment Clinical Trial Websites Recruitment Technology Recruitment Technology Engagement Site Engagement Patient Engagement Analytics Platforms and Complance Insights About 2nd Bi-Annual CORE Symposium: April 15, 2026 at … ealTime eClinical Solutions Lauren Briggs, ProofPilot 4:00 - 5:00: Change Agent Award Presentation & Cocktail Hour Change Agent Awards At CORE Symposium in 2025, we presented our first-ever Change Agent Award to Jenn Curry of Biogen! We're excited to honor yet another resilient and hard-working change agent live at Fenway on April 15. Learn more and nominate someone for the award here . Who will be there ? The CORE Symposium is tailored to clin ops lead
Leadership Team - cyclotherapeutics Purpose Overview Team Leadership Team Patients and Families Our Commitment Patient Resources Community Stories Ongoing Clinical Trials TransportNPC: Phase 3 Study in Niemann-Pick Disease Type C Expanded Access Program Science Trappsol ® Cyclo™ Scientific Publications Pipeline Pipeline Niemann-Pick Disease Type C News/Events News Email Alerts Contact Select Page Leadership Team Leadership Team Our leadership team at Cyclo brings deep and diverse experience across research, drug development, and commercialization, with a particular expertise in rare diseases a
Rafael Holdings - Home - Rafael Holdings News | Investors Investor Overview Stockholder Services Tax Documents Presentations Corporate Governance Annual Reports Proxy Statements Quarterly Earnings SEC Filings Email Alerts Contact Investor Relations CONTACT US Rafael Holdings Navigation Cyclo Therapeutics Leadership Executive Management Board of Directors Cyclo Therapeutics Leadership Executive Management Board of Directors Rafael Holdings is a clinical stage biotechnology company focused on helping patients with difficult to treat diseases. Our recent merger with Cyclo Therapeutics, brings tog … ics and integrity with an approachable and pragmatic style to communication and application. Strong sense of accountability and ownership; proactive and self-motivated. Highly collaborative; ability to work independently and as a teammate; ability and desire to lead, influence and collaborate cross-functionally. Thrive in a fast-paced, lean, highly dynamic environment. Ability and willingness to travel. What You’ll Get To be a part a growing company and fantastic team … ns for qualified individuals with disabilities and disabled veterans in our job application procedures. If you need assistance due to a disability, you may contact us at [email protected] CLOSE
Cyclo Therapeutics - Leadership Team | The Org Platform Enrich Pricing Log in Sign up Cyclo Therapeutics Teams Leadership Team Unverified Leadership Team 6 people · 0 jobs The Leadership Team at Cyclo Therapeutics is responsible for setting the strategic direction and vision of the company, overseeing clinical development and regulatory compliance, and ensuring efficient operational execution. This diverse team, comprised of experts in medical affairs, business development, patient advocacy, and finance, collaborates to drive innovation in cyclodextrin-based therapies and to facilitate succe
Cyclo Therapeutics logs efficacy win in pivotal Niemann-Pick disease trial - Clinical Trials Arena Skip to site menu Skip to page content Switch language: .translate --> CT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Approvals Operations Outsourced Services Supply Chain Data Management Medical Devices Themes Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insights Deals Jobs Filings Patents Social Media Companies Company … Chain Data Management Medical Devices Latest Ollin Biosciences secures $330m to fund Phase III OLN324 trials Viking Therapeutics commences Phase I trial of VK3019 Ascletis receives FDA clearance for Phase I trial of obesity treatment Themes Sections Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Foreign Direct Investment Latest How wearables can unlock their full potentia
%PDF-1.7 %���� 1 0 obj >/Metadata 2862 0 R/ViewerPreferences 2863 0 R>> endobj 2 0 obj > endobj 3 0 obj >/XObject >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 960 540] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x���]K�0�� ���DX�s�����?A�\AD����jW/��&U�s�c�ś���I�NY�&㬂�U^|O� ���,cH��$���� ���³�������biHFz�zr�{C߃�5��/����tkGD nNq˩�^��f������~_V��(��]�A C��i���Mm�SjC:qlΎ�9H�MI` ��>����mI'�i=��P6�o�|� �;��q�1vD��C��w'���x����N���D����U�J��lC��)̞�Jh|�K������� �ldV.�;8x��l�-��"Mȴ#i�R���A9�V �؆a����+�/�#h�(���}�� �� �\
%PDF-1.6 %���� 1311 0 obj > endobj 1320 0 obj >/Filter/FlateDecode/ID[ ]/Index[1311 16]/Info 1310 0 R/Length 68/Prev 1790610/Root 1312 0 R/Size 1327/Type/XRef/W[1 3 1]>>stream h�bbd```b``^"_�IE��L�$&Ad�z �x"H�߸�����u H � �����?� endstream endobj startxref 0 %%EOF 1326 0 obj >stream h�b```�� l � B ���� � " � �,̌"� ��: >/Metadata 191 0 R/OCProperties >/OCGs[1321 0 R]>>/Outlines 253 0 R/PageLayout/SinglePage/Pages 1306 0 R/StructTreeRoot 292 0 R/Type/Catalog>> endobj 1313 0 obj >/Font >/Properties >/XObject >>>/Rotate 0/StructParents 0/Tabs/S/Type/Page>> endobj 1314 0 obj >st … :758dc5cc-682e-4941-bb98-2c75ac7daea7 uuid:36aa7120-330f-41a1-a1bc-b27847a335ad application/pdf 03/21 Justin Romanowski Adobe PDF Library 21.11.71 0x010100FA8937C8BE42904D9A39E9C8F3B6ED9D endstream endobj 192 0 obj >stream hޔO��0 ��A�#U]Y��b�D�X�2��4�È`s� z@ �\(�� I�)@ש��y]���_NˡJF� I� ���g5�����蚏 ��d�봁������i��I��9(�#��#��B�f�V�[K�m� �$'����[��.Y^ endstream endobj 193 0 obj >stream h�l�Qk�0࿒7�ͽ��f�P�6&�� HmƂ[��[�ocO㼞� ��f#�?)�ӅC���"]/�Pʆ"�ȇ�ٿ��s��+�
Cyclo Therapeutics to Present at the JMP Securities Life Sciences Conference - cyclotherapeutics Purpose Overview Team Leadership Team Patients and Families Our Commitment Patient Resources Community Stories Ongoing Clinical Trials TransportNPC: Phase 3 Study in Niemann-Pick Disease Type C Expanded Access Program Science Trappsol ® Cyclo™ Scientific Publications Pipeline Pipeline Niemann-Pick Disease Type C News/Events News Email Alerts Contact Select Page News Email Alerts News Cyclo Therapeutics to Present at the JMP Securities Life Sciences Conference Jun 9, 2021 Live video webcast presenta
Cyclo Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results - cyclotherapeutics Purpose Overview Team Leadership Team Patients and Families Our Commitment Patient Resources Community Stories Ongoing Clinical Trials TransportNPC: Phase 3 Study in Niemann-Pick Disease Type C Expanded Access Program Science Trappsol ® Cyclo™ Scientific Publications Pipeline Pipeline Niemann-Pick Disease Type C News/Events News Email Alerts Contact Select Page News Email Alerts News Cyclo Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results Aug 1
Presentations - cyclotherapeutics Purpose Overview Team Leadership Team Patients and Families Our Commitment Patient Resources Community Stories Ongoing Clinical Trials TransportNPC: Phase 3 Study in Niemann-Pick Disease Type C Expanded Access Program Science Trappsol ® Cyclo™ Scientific Publications Pipeline Pipeline Niemann-Pick Disease Type C News/Events News Email Alerts Contact Select Page News Email Alerts Presentations Our Clinical Studies Our Pipeline Sign up for Alerts Trappsol ® Cyclo™ is not currently approved for any indication. Third-party websites are provided for convenience onl
Expanded Access Program - cyclotherapeutics Purpose Overview Team Leadership Team Patients and Families Our Commitment Patient Resources Community Stories Ongoing Clinical Trials TransportNPC: Phase 3 Study in Niemann-Pick Disease Type C Expanded Access Program Science Trappsol ® Cyclo™ Scientific Publications Pipeline Pipeline Niemann-Pick Disease Type C News/Events News Email Alerts Contact Select Page Our Commitment Patient Resources Community Stories Ongoing Clinical Trials TransportNPC: Phase 3 Study Expanded Access Program Expanded Access to Investigational Medicines Cyclo Therapeutics,
News - cyclotherapeutics Purpose Overview Team Leadership Team Patients and Families Our Commitment Patient Resources Community Stories Ongoing Clinical Trials TransportNPC: Phase 3 Study in Niemann-Pick Disease Type C Expanded Access Program Science Trappsol ® Cyclo™ Scientific Publications Pipeline Pipeline Niemann-Pick Disease Type C News/Events News Email Alerts Contact Select Page News Email Alerts News Our Pipeline Our Science Sign up for Alerts Trappsol ® Cyclo™ is not currently approved for any indication. Third-party websites are provided for convenience only. Cyclo Therapeutics, LLC
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Cyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer’s Disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing D … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Cyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer’s Disease January 9, 2023 | 5 min read Twitter LinkedIn Facebook Email Print Cyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol ® Cyc … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Rafael Holdings merges with Cyclo Therapeutics | David Polinsky posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to Li
Cyclo Therapeutics, Inc. – NNPDF Skip to content About Us About Us Board of Directors Scientific Advisory Board Staff Membership International Niemann-Pick Disease Alliance Donations Volunteer Diseases Niemann-Pick ASMD Niemann-Pick NPC Family Support Support Services Advocacy Bringing Holiday Cheer ASMD and NPC Care Clinics Family Assistance and Support Program Family Events Family Support & Medical Conference Family Experiences Family Resources International Niemann-Pick Disease Registry Memorials National Family Caregivers Month Newborn Screening Niemann-Pick Awareness Month Rare … ilored to the needs and preferences of patients. For more information on how to apply for this financial assistance, please contact Laurie Turner, Family Services Manager at [email protected] . For more information on the PFDD, or to register for the event, visit niemannpickc-pfdd.com . 2/28/2019 jjb CTD Reports Initial Data for Two Clinical Trials of Trappsol® Cyclo™ Provided Intravenously for Patients with Niemann-Pick Disease Type C CLICK HERE FOR COMPLETE ANNOUNCEMEN … TE ANOUNCEMENT 09/28/2017 jjb CTD Holdings Announces Approval of Clinical Trial Application to Conduct Phase I/II Clinical Study of Trappsol(R) Cyclo(TM) in Patients with Niemann-Pick Type C Disease in Israel CLICK HERE FOR COMPLETE ANNOUNCEMENT CTD Holdings Announces First Patient Dosed in Phase I/II Clinical Trial to Evaluate Trappsol(R) Cyclo(TM) in Niemann-Pick disease Type C CLICK HERE FOR COMPLETE ANNOUNCEMENT 07/20/2017 jjb CTD Holdings Ships Additional Trappsol® Cyclo … ICK HERE FOR FULL ANNOUNCEMENT 01/17/2017 jjb CTD Holdings Files Clinical Trial Application with Italian Drug Agency to Continue Advancing Trappsol(R) Cyclo(TM) Drug Development Program to Treat Niemann-Pick disease Type C CLICK HERE FOR FULL ANNOUNCEMENT 12/22/2016 jjb CTD HOLDINGS IV TRAPPSOL CYCLO STUDY The NNPDF Central Office has received notice that CTD’s US trial parameters for the IV Trappsol Cyclo study in NPC are now published at Clinical Trials.Gov. CTD HOLDINGS PR … D HOLDINGS PRESS RELEASE CTD Holdings Announces MHRA Approval of Clinical Trial Application for Treatment of NPC With Trappsol(R) Cyclo(TM) CLICK HERE FOR FULL RELEASE 09/29/2016 jjb Supporting one another. Supporting our community Donate Now Membership Volunteer Facebook Instagram Linkedin Twitter About Diseases Family Support Research Resources
Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1 - cyclotherapeutics Purpose Overview Team Leadership Team Patients and Families Our Commitment Patient Resources Community Stories Ongoing Clinical Trials TransportNPC: Phase 3 Study in Niemann-Pick Disease Type C Expanded Access Program Science Trappsol ® Cyclo™ Scientific Publications Pipeline Pipeline Niemann-Pick Disease Type C News/Events News Email Alerts Contact Select Page News Email Alerts News Cyclo Therapeutics Achieves Lan … ed for H1 2025 If 48-week data demonstrate significance, submission of New Drug Application (NDA) to the Food and Drug Administration (FDA) and Marketing Authorization Application (MAA) to European Medicines Agency (EMA) is targeted for 2H 2025; Qualification for Priority Review Voucher (PRV) upon NDA submission GAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology comp … stical significance, the Company, in alignment with the FDA and EMA, intends to submit marketing applications for approval based on the 48-week interim data. The Company’s ongoing single-arm sub-study is evaluating patients from birth to less than 3 years of age with NPC1 irrespective of symptoms to evaluate safety and to obtain descriptive data on global disease severity and the response to Trappsol ® Cyclo™. The substudy is being conducted in countries outs
Management News | Investors CONTACT US Rafael Holdings Navigation Cyclo Therapeutics Leadership Board of Directors Executive Management Leadership Board of Directors Executive Management Investors Investors Management Executive Management Howard S. Jonas Chairman of the Board and Chief Executive Officer Howard S. Jonas has served as Chairman of the Board of Directors of the Company since August 17, 2017 and as Executive Chairman since June 13, 2022. He has served as Chief Executive Officer since July 2025 and previously served in that capacity from March 8, 2018 through April 30, 2021. M
10-K 1 ctdh20191231_10k.htm FORM 10-K ctdh20191231_10k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2019 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the period from ____________ to ___________ Commission file number 0-25466 CYCLO THERAPEUTICS, INC. (Exact … g twelve months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smalle … lo™ as a treatment for NPC. In 2016, we filed an Investigational New Drug application (“IND”) with the FDA, which describes our Phase I clinical plans for a randomized, double blind, parallel group study at a single clinical site in the U.S. The Phase I study will evaluate the safety of Trappsol ® Cyclo™ along with markers of cholesterol metabolism and markers of NPC during a 14-week treatment period of intravenous administration of Trappsol ® … 8482; for the treatment of this disease, and in October 2018, we filed a patent application with respect to the use of hydroxypropyl beta cyclodextrins in the treatment of Alzheimer's disease. In October 2019 we entered into an agreement with Worldwide Clinical Trials, a Contract Research Organization, to conduct a clinical trial to evaluate the safety and efficacy of Trappsol® Cyclo™ for the treatment of Alzheimer’s disease. We also continue to operat … Since the property modifications achieved are often advantageous to a specific application, the Company does not believe the loss of the natural product categorization will prevent its ultimate pharmaceutical use. It does, however, create a greater regulatory burden. Use of Cyclodextrins to Treat NPC Natural cyclodextrins have been
Cyclo Therapeutics Enters Research and Collaboration Agreement with Wits Commercial Enterprise (Pty) Ltd to Explore Potential Applications of Trappsol® Cyclo™ to Expand Pipeline - cyclotherapeutics Purpose Overview Team Leadership Team Patients and Families Our Commitment Patient Resources Community Stories Ongoing Clinical Trials TransportNPC: Phase 3 Study in Niemann-Pick Disease Type C Expanded Access Program Science Trappsol ® Cyclo™ Scientific Publications Pipeline Pipeline Niemann-Pick Disease Type C News/Events News Email Alerts Contact Select Page News Email Alerts News Cycl
Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals News | Investors CONTACT US Rafael Holdings Navigation Cyclo Therapeutics Leadership Board of Directors Executive Management Leadership Board of Directors Executive Management Investors Investors News Search: PDF Print View All Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Typ
Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement - cyclotherapeutics Purpose Overview Team Leadership Team Patients and Families Our Commitment Patient Resources Community Stories Ongoing Clinical Trials TransportNPC: Phase 3 Study in Niemann-Pick Disease Type C Expanded Access Program Science Trappsol ® Cyclo™ Scientific Publications Pipeline Pipeline Niemann-Pick Disease Type C News/Events News Email Alerts Contact Select Page News Email Alerts News Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement Aug 22, 2024 Cyclo Therapeutics&# … rtible notes through closing. Following the closing, Rafael Holdings intends to fund the TransportNPC™ clinical trial to its 48-week interim analysis. The boards of directors of Rafael Holdings and Cyclo Therapeutics have approved this transaction and expect it to close in late 2024, pending approval of the companies’ shareholders, the effectiveness of a registration statement to register the shares of Class B common stock of Rafael Holdings to be issued in the tr
SEC Filings - cyclotherapeutics Purpose Overview Team Leadership Team Patients and Families Our Commitment Patient Resources Community Stories Ongoing Clinical Trials TransportNPC: Phase 3 Study in Niemann-Pick Disease Type C Expanded Access Program Science Trappsol ® Cyclo™ Scientific Publications Pipeline Pipeline Niemann-Pick Disease Type C News/Events News Email Alerts Contact Select Page News Email Alerts SEC Filings For Patients Our Pipeline Sign up for Alerts Trappsol ® Cyclo™ is not currently approved for any indication. Third-party websites are provided for convenience only. Cyclo The
Cyclo Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - cyclotherapeutics Purpose Overview Team Leadership Team Patients and Families Our Commitment Patient Resources Community Stories Ongoing Clinical Trials TransportNPC: Phase 3 Study in Niemann-Pick Disease Type C Expanded Access Program Science Trappsol ® Cyclo™ Scientific Publications Pipeline Pipeline Niemann-Pick Disease Type C News/Events News Email Alerts Contact Select Page News Email Alerts News Cyclo Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update Aug 1 … -Pick Type C1. If 48-week data demonstrate significance, submission of New Drug Application (NDA) to the Food and Drug Administration (FDA) and Marketing Authorization Application (MAA) to European Medicines Agency (EMA) is targeted for 2H 2025; Qualification for Priority Review Voucher (PRV) upon NDA submission; Continued NPC community engagement through attendance at the Latin American School of Medical and Human Genetics Annual Meeting (ELAG), Australian NPC Foundation Con … ortugal; and Received a notice from the European Patent Office of a decision to grant European patent application No. 19805439.7 titled, “ Methods for Treating Alzheimer’s Disease ” under European patent number 3873604B. The notice states that mention of the decision will be published on August 21, 2024 in European Patent Bulletin 24/34 and will take effect on that date. Summary of Financial Results for the Second Quarter 2024 Net loss for the quarter ended
To afford urgent access to a potential-disease modifying treatment, Dr. Diana Kerwin, in partnership with CTD Holdings, the manufacturer of Trappsol (R) Cyclo(TM), will administer the product to a patient with Alzheimer's Disease who has no other disease-modifying treatment options.
ROTH 36th Annual Conference 2024 | B2i Digital Featured Conference FEATURED CONFERENCES VIEW ALL FEATURED CONFERENCES Upcoming In-Person Conferences ROTH 5th Annual Healthcare Opportunities Conference NIBA 153rd Investment Conference ROTH 13th Annual Solar & Storage Symposium at RE+ ROTH 15th Annual Technology Conference ROTH 15th Annual Deer Valley Event ROTH 39th Annual Conference Upcoming Virtual Conferences Virtual Investor Conferences Life Sciences Investor Forum Virtual Investor Conferences Global Technology Investor Conference Virtual Investor Conferences Precious Metals & Criti … registration is subject to approval. If you are interested in attending, please submit a registration request using the Register link or contact your ROTH MKM Representative. B2I DIGITAL, Inc.is a marketing sponsor of the 36th Annual ROTH Conference. B2I DIGITAL, Inc. is not an affiliate of Roth MKM and is not authorized to represent or act on behalf of Roth MKM, in any capacity. Roth MKM has not reviewed and approved the content contained on the b … ducts) and iii) Precision Agriculture innovation (including SIMPAS prescriptive application and Ultimus measure/record/verify technologies). American Vanguard is included in the Russell 2000 and Russell 3000 Indexes. VIEW IR WEBSITE American Vanguard Corporation is a diversified specialty and agricultural products company that develops, manufactures, and markets solutions for crop protection and nutrition, turf and ornamentals management, commercial and consumer pest control. … ducts) and iii) Precision Agriculture innovation (including SIMPAS prescriptive application and Ultimus measure/record/verify technologies). American Vanguard is included in the Russell 2000 and Russell 3000 Indexes. VIEW IR WEBSITE Consumer POWW AMMO, Inc. (POWW) AMMO, Inc. (POWW) AMMO, Inc. is the owner of GunBroker.com, the largest online marketplace serving the firearms and shooting sports industries, and a leading vertically integrated producer of high-performance ammuni … eliable domestic supply of innovative, hard-to-source, high-demand products. We apply our extensive expertise to develop groundbreaking solutions to remove harmful chemicals and pollutants from water, land and air. VIEW IR WEBSITE Arq is a diversified, environmental technology company with products that enable a cleaner and safer planet while act
%PDF-1.7 1967 0 obj > endobj 2042 0 obj ] /Type /XRef /Size 2107 /Index [ 1967 140 ] /W [ 1 3 1 ] /Filter /FlateDecode /DecodeParms > /Length 257 >> stream x�cbd`�b`� �!D�l��z �; ���L�$�� 6'X�?� �S��?���`�0)&W���`�D2/��Af����D�"U �ƙ ��$����dP�"+��Hi-��K����LE`���� � ���f/�������f!D�� � SlN�8D� $đ�d � > stream x��W{LSW��}ܶ, �(��U�V���)ӫ� ��fn��`����D��E]�ŝ�9���^���w�� @0 �* �N��йr����h�W�!�F��ëPT:k`�J�, _���C ?+�]#a���ohR�m����?���p��$��ݵv�3$[� v5� �0g���-�C&�����[���՞�'U\�fIW.�;��$����R?������J?��or�.��g$zS ����9��Z���e��ex=���ق9�;Sn�� fGy�S��� … ������k��}���>Mv,����������u FgS�$^�P endstream endobj 1988 0 obj > stream application/postscript CHI_horiz_tagline Thomas Norton 2019-12-04T11:03:49-05:00 2019-12-04T11:03:49-05:00 2019-12-04T11:03:49-05:00 Adobe Illustrator 24.0 (Windows) xmp.iid:55a22ad4-aa29-274f-86ac-dcd2de025ae2 xmp.did:55a22ad4-aa29-274f-86ac-dcd2de025ae2 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:954a384f-a006-4c4a-b0d0-7af86daf9eca xmp.did:954a384f-a006-4c4a-b0d0-7af86daf9eca uuid:5 … 2015-08-04T13:03:45-04:00 Adobe Illustrator CC 2014 (Windows) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:f8a28696-ef3d-7044-807e-bf770af655f3 2015-08-04T13:06:12-04:00 Adobe Illustrator CC 2014 (Windows) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:b9487eb8-4b46-4c4e-89f5-de81e9732de5 2015-08-04T14:00:01-04:00 Adobe Illustrator CC 2014 (Windows) / converted from application/postscri … Adobe Illustrator CC 2014 (Windows) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:36804d38-2635-314a-9a24-1d7f0aa4f03b 2015-12-22T11:20:55-05:00 Adobe Illustrator CC 2015 (Windows) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:954a384f-a006-4c4a-b0d0-7af86daf9eca 2015-12-22T11:23:08-05:00 Adobe Illustrator CC 2015 (Windows) / converted from application/postscript to application/vnd.adob … 018-06-21T11:24:39-04:00 Adobe Illustrator CC 22.0 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:bd15db29-50fa-424f-9cf3-1ef83994cd9f 2019-02-08T11:24:38-05:00 Adobe Illustrator CC 23.0 (Macintosh) / saved xmp.iid:c493610d-08eb-497c-b03f-562fc4304b56 2019-02-08T11:24:53-05:00 Adobe Illustra
Nonprofits Drive Drug Development in Rare Diseases | Alexandra Heumber Perry posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, yo
%PDF-1.3 %��������� 4 0 obj > stream x��Mo�0 �����xNj3�(�R�}� (v,``݂u�������R�� �v>дM����~�x��� ��ъ����� �½V"�Ȣ��K� ��Ő��Q|�D���_�. �����ۋ�`7��´���D��Iل�ʵ����2�"�G w(P �6�O�u�q��x ݛ�y[��wM��zsR�C���n��Թ��n-��;��zX �0���Q�$��` As1���2�3$���n&�䘨���H�E�����** �);�%Y�I�ӫf�pPۆ�� ˪��ɦ�f� ż�m9N��O,��1ٰp�]��>�OߟŅV�L��҂E �H�]净 ?�Y��� ���j���F� ���U�5@�qz� �9��IM�/��e�����ݪ�֪ �~��y�Q�� endstream endobj 5 0 obj 414 endobj 2 0 obj > endobj 6 0 obj > /ExtGState > /Font > /XObject > >> endobj 7 0 obj > stream ����Adobed��#"/ A1/6>8@X@8>DDDDDDDDDDDDDDDDDDDDDD
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Niemann-Pick UK - We are pleased to share the latest... Facebook Log In Niemann-Pick UK's Post Niemann-Pick UK September 8, 2020 · Shared with Public We are pleased to share the latest update from Cyclo Therapeutics Inc entitled Cyclo Therapeutics Inc. Announces Additional Efficacy Data from its Ongoing Phase I/II Trial using Trappsol® CycloTM Intravenously to Treat Patients with Niemann-Pick Disease Type C1 (NPC1): "...the group data show that six of the seven patients (86% of those who completed) met the primary endpoint of the Phase I/II study, which was to achieve at least a one-
%PDF-1.7 %���� 1 0 obj >/Metadata 1908 0 R/ViewerPreferences 1909 0 R>> endobj 2 0 obj > endobj 3 0 obj >/Font >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 612 792] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��WYO#G~���PO��jiw��BZ�E��`#Eyp�a��M�����TO� >1�e آ��h�����C (N�J-Q�^���v��O�i x��:��C6��]��V�c �c�b� ��� �9P!.{� ��� ����}����LX���&��c����`�=����L� ��9Z���e9 .�����g�S~j� i:��1̭ �/7��硜��yx�� (�ׇ��vV֜�N��0��ɾ��8k��X�خ)��x����Nh,S��7�Ө��W$�Hu;a�����$��[�@R�V�SiYE(��m%�V��$�$�lY6uTN���4Z�����TV�_����� �`SL\I
%PDF-1.6 %���� 2804 0 obj > endobj 2821 0 obj >/Filter/FlateDecode/ID[ ]/Index[2804 29]/Info 2803 0 R/Length 98/Prev 1798414/Root 2805 0 R/Size 2833/Type/XRef/W[1 3 1]>>stream h�bbd```b``����A$S X� �d�y ���A��Z� DF����@�Y6Dr�I���@�q�a ���#X/� ��� ?��[@ endstream endobj startxref 0 %%EOF 2832 0 obj >stream h�b```�� , B9 " �� �, ��� .�]�� T��UAì��e��) mβ�{�g��s��;��J��g�D��J�LF�j/%/2X�Kp¦ݯ��5���\�+�h&�}�.FB�7�=� ae)Q���n{�ٱŇ/ 0�tt0 UIF��Zށ���`.;X�PzDTP $܁ñ@G�3H6�i~ �;;�A�����A��q*C[�҇Δ�0�G *J�9>�L8}���5���;�m`~�pOH������� �����m�0�� �Ԗ�@�h�$��g��v … :c15f3520-bd2c-4f5d-a033-358ec7bc45b0 uuid:500687d4-091c-46da-8b8f-4af1bfa212de application/pdf Sponsorship Opportunities Tara Coleman Adobe PDF Library 25.1.20 endstream endobj 91 0 obj >stream h�2�00R0P���w�/�+Q����L)�6�00 )�IK�1������1D� D��D��T��$����Q�� endstream endobj 92 0 obj >stream h�l�� �@��W���!�V� B�$� �:�R�ȸ�}ѩ��z� �y��|�^�(�N�T\oٕ�SXn5�l�Z�&I���1�V�o��.�������5?Ij�Ϋ�����?�f��> m#F^3-#�*�X�� >/Filter/FlateDecode/ID[ ]/Info 2803 0
Community News – NNPDF Skip to content About Us About Us Board of Directors Scientific Advisory Board Staff Membership International Niemann-Pick Disease Alliance Donations Volunteer Diseases Niemann-Pick ASMD Niemann-Pick NPC Family Support Support Services Advocacy Bringing Holiday Cheer ASMD and NPC Care Clinics Family Assistance and Support Program Family Events Family Support & Medical Conference Family Experiences Family Resources International Niemann-Pick Disease Registry Memorials National Family Caregivers Month Newborn Screening Niemann-Pick Awareness Month Rare Disease Da … announced that the U.S. Food and Drug Administration has accepted its New Drug Application for adrabetadex in infantile-onset Niemann-Pick disease type C (NPC) and granted Priority Review, with a PDUFA date of August 17, 2026. This acceptance is an important milestone, reflecting the significant unmet need in infantile-onset NPC and incorporating feedback from the FDA and the NPC community. Read the complete press release . 03/02/2026 Update from Mandos Health Mandos Health … Therapeutics is pleased to announce the filing of their Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for arimoclomol. This marks a major milestone in the company’s journey toward making MIPLYFFA foundational therapy available to patients with NPC across Europe. Read the complete announcement. 07/29/2025 Update from Mandos Health Mandos Health has shared the following February 2025 update with the NNPDF community. Read the complete update … needed treatment of NPC, and their goal is to resubmit the arimoclomol New Drug Application (NDA) to the FDA by the end of 2023. Read the complete announcement . Please contact Joslyn Crowe, NNPDF Executive Director, with any questions. 11/20/2023 Update from Bloomsbury Genetic Therapies Bloomsbury Genetic Therapies Receives Orphan Drug Designations from the European Commission and the US FDA for BGT-NPC for the Treatment of Niemann-Pick Disease Type C and Provides Update on … (NPC). The Company also received a detailed Type B Pre-Investigational New Drug Application (IND) Written Response from the FDA, providing constructive feedback on the Company’s plans for chemistry, manufacturing, and controls (CMC), non-clinical and clinical development for BGT-NPC. Read the complete announcement. 10/17/2023 Update from Cyclo Th
Niemann-Pick UK - Update on NPC Phase 3 Study from Cyclo... Facebook Log In Niemann-Pick UK's Post Niemann-Pick UK June 13, 2023 · Shared with Public Update on NPC Phase 3 Study from Cyclo Therapeutics, Inc. We have news to share in behalf of Cyclo Therapeutics regarding their Phase 3 study, TransportNPC™, for Niemann Pick Type C1 (NPC): “…our Global Principal Investigator and Head of the Global Steering Committee is delighted to update you on the remarkable progress we've made so far in advancing this pivotal study. TransportNPC™ is an advanced program that aims to evaluate the safe
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Home - cyclotherapeutics Purpose Overview Team Leadership Team Patients and Families Our Commitment Patient Resources Community Stories Ongoing Clinical Trials TransportNPC: Phase 3 Study in Niemann-Pick Disease Type C Expanded Access Program Science Trappsol ® Cyclo™ Scientific Publications Pipeline Pipeline Niemann-Pick Disease Type C News/Events News Email Alerts Contact Select Page Dedicated to developing life-changing medicines for patients and families living with rare and neurological disorders. Our Purpose Our Pipeline Dedicated to developing life-changing medicines for patients and fa
Facebook Explore the things you love . Log into Facebook Email or mobile number Password Log in Forgot password? Create new account English (US) فارسی العربية Türkçe Deutsch Français (France) Polski More languages… Sign Up Log In Messenger Facebook Lite Video Meta Pay Meta Store Meta Quest Ray-Ban Meta Meta AI Instagram Threads Privacy Policy Privacy Center About Create ad Create Page Developers Careers Cookies Ad choices Terms Help Contact Uploading & Non-Users Meta © 2026
Cyclo Therapeutics Announces Abstract Accepted for Poster Presentation at the 14th International Congress of Inborn Errors of Metabolism (ICIEM) - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manu … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Cyclo Therapeutics Announces Abstract Accepted for Poster Presentation at the 14th International Congress of Inborn Errors of Metabolism (ICIEM) October 18, 2021 | 5 min read Twitter LinkedIn Facebook Email Print Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), today announced its abstrac … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kinder-and-gentler-join-biospace-at-bio-to-find-out" > Antibody-drug conjugate Can ADCs be kinder and gentler? Join BioSpace at BIO to find out June 23, 2026 ·&n … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Cyclo Therapeutics Appoints Gerald F. Cox, MD, PhD as Acting Chief Medical Officer - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Canc … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Cyclo Therapeutics Appoints Gerald F. Cox, MD, PhD as Acting Chief Medical Officer March 1, 2021 | 6 min read Twitter LinkedIn Facebook Email Print Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company developing cyclodextrin-b … at San Diego and his B.A. from Harvard College. He completed an internship and residency in pediatrics followed by clinical and post-doctoral research fellowships in genetics at Boston Children’s Hospital and was Director of the Medical Genomics Mapping Facility. Dr. Cox is board-certified by the American College of Medical Genetics and Genomics in Clinical, Biochemical, and Molecular Genetics, and he was board-certified by the American Academy of Pediatrics in the past. He … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deal … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease March 14, 2024 | 3 min read Twitter LinkedIn Facebook Email Print Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”) today announced the United States Patent and … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc. - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Deals Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc. December 27, 2023 | 5 min read Twitter LinkedIn Facebook Email Print Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. announced the closing of its previously announced transaction pursuant to which AMT w … h runway extended into 2H 2024 with approximately $11.0 million cash on hand to fund operations GAINESVILLE, Fla.--( BUSINESS WIRE )-- Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company focused on developing transformative therapies for rare and neurological diseases with limited treatment options, and Applied Molecular Transport Inc. (Nasdaq: AMTI) (“AMT”), a biopharmaceutical company, announced today the c … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. Explore News Jobs Newslett … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old) - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufact … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old) February 7, 2025 | 9 min read Twitter LinkedIn Facebook Email Print First data in NPC1 on treatment in this age group over a period of 48 weeks At 24 weeks of the su … stical significance, the Company, in alignment with the FDA and EMA, intends to submit marketing applications for approval to market Trappsol ® Cyclo™ based on the 48-week interim data. In addition to the oral presentation given by Dr. Spiegel, the Company had two posters presented by Dr. Caroline Hastings, Pediatric hematologist oncologist, Director of Neuro-oncology, and Professor of Pediatrics at UCSF Benioff Children’s Hospital Oakland titled, “ Trappsol ® Cyclo™ (HPβCD) … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Cyclo Therapeutics Reports Second Quarter 2023 Financial Results - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Cyclo Therapeutics Reports Second Quarter 2023 Financial Results August 15, 2023 | 4 min read Twitter LinkedIn Facebook Email Print Cyclo Therapeutics, Inc. today reported its financial results for the second quarter 2023. Continued strong enrollment of pivotal Phase 3 global study (Tr … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Developme … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1 May 30, 2024 | 7 min read Twitter LinkedIn Facebook Email Print Cyclo Therapeutics, Inc. today announced the last patient has bee … ed for H1 2025 If 48-week data demonstrate significance, submission of New Drug Application (NDA) to the Food and Drug Administration (FDA) and Marketing Authorization Application (MAA) to European Medicines Agency (EMA) is targeted for 2H 2025; Qualification for Priority Review Voucher (PRV) upon NDA submission GAINESVILLE, Fla.--( BUSINESS WIRE )-- Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company … stical significance, the Company, in alignment with the FDA and EMA, intends to submit marketing applications for approval based on the 48-week interim data. The Company’s ongoing single-arm sub-study is evaluating patients from birth to less than 3 years of age with NPC1 irrespective of symptoms to evaluate safety and to obtain descriptive data on global disease severity and the response to Trappsol ® Cyclo™. The substudy is being conducted in countries outside of the United … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Cyclo Therapeutics to Present at 8th Annual Dawson James Conference - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Pre … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Cyclo Therapeutics to Present at 8th Annual Dawson James Conference October 5, 2023 | 2 min read Twitter LinkedIn Facebook Email Print Cyclo Therapeutics, Inc. today announced that N. Scott Fine, Chief Executive Officer and Joshua Fine, Chief Financial Officer of Cyclo Therapeutics will present at the 8th Annual Dawson … tion structure and strategy including direct investment through our independent fund. Our team will assist in crafting your vision and shaping your message for the capital markets. Headquartered in Boca Raton, FL, Dawson James is privately held with offices in New York, Maryland, and New Jersey. www.dawsonjames.com View source version on businesswire.com: https://www.businesswire.com/news/home/20231005589716/en/ Contacts Investor Contact: JTC Team, LLC Jenene Thomas (833) 475 … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kinder-and-gentler-join-biospace-at-bio-to-find-out" > Antibody-drug conjugate Can ADCs be kinder and gentler? Join BioSpace at BIO to find out June 23, 2026 ·&n … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Cyclo Therapeutics Inc. Announces Additional Efficacy Data from its Ongoing Phase I/II Trial using Trappsol® CycloTM Intravenously to Treat Patients with Niemann-Pick Disease Type C1 (NPC1) - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRI … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Cyclo Therapeutics Inc. Announces Additional Efficacy Data from its Ongoing Phase I/II Trial using Trappsol® CycloTM Intravenously to Treat Patients with Niemann-Pick Disease Type C1 (NPC1) September 8, 2020 | 4 min read Twitter LinkedIn Facebook Email Print Cyclo Therapeutics, Inc. ( … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Cyclo Therapeutics Announces Pricing of $12.5 Million Public Offering - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions P … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Cyclo Therapeutics Announces Pricing of $12.5 Million Public Offering December 9, 2020 | 4 min read Twitter LinkedIn Facebook Email Print Cyclo Therapeutics, Inc. (“Cyclo Therapeutics” or the “Company”) (NasdaqCM: CYTH) (NasdaqCM:CYTHW), a clinical stage biotechnology company developing a cyclodextrin platform for the t … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Cyclo Therapeutics Commences Commercial-Scale Manufacturing for Trappsol® Cyclo™ - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Cyclo Therapeutics Commences Commercial-Scale Manufacturing for Trappsol® Cyclo™ July 27, 2021 | 5 min read Twitter LinkedIn Facebook Email Print Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through … ics received positive feedback supporting the Company’s development strategy to submit an Initial New Drug (IND) application for a Phase 2 study of intravenous Trappsol ® Cyclo™ in the treatment of early Alzheimer’s disease. The Company is on track to file its IND for a Phase 2 study of Alzheimer’s disease in the second half of 2021. About Cyclo Therapeutics Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines thro … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin